Structural Basis for the Recognition of Human Cytomegalovirus Glycoprotein B by a Neutralizing Human Antibody

PLoS Pathogens

Volumn 10, Issue 10, 2014, Pages

  Spindler, Nadja ^a   Diestel, Uschi ^a   Stump, Joachim D ^a   Wiegers, Anna Katharina ^a   Winkler, Thomas H ^b   Sticht, Heinrich ^a   Mach, Michael ^a   Muller, Yves A ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS GLYCOPROTEIN B DOM II; GLYCOPROTEIN B; HUMAN ANTIBODY SM5 1; HUMAN MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; GLYCOPROTEIN B, SIMPLEXVIRUS; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

AMINO ACID SUBSTITUTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ARTICLE; BINDING SITE; CRYSTALLIZATION; CYTOMEGALOVIRUS; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SIMULATION; SOMATIC MUTATION; CHEMISTRY; CYTOMEGALOVIRUS INFECTIONS; GENETICS; HUMAN; IMMUNOLOGY;

HUMAN HERPESVIRUS 5;

AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; VIRAL ENVELOPE PROTEINS;

EID: 84908324649     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004377     Document Type: Article

References (69)

1. Britt W (2006) Human cytomegalovirus infections and mechanisms of disease. In: Reddehase MJ, editor. Cytomegaloviruses: molecular biology and immunology. Norfolk (UK): Caister Academic Press. pp. 1–28.
2. Kenneson A, Cannon MJ, (2007) Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17: 253–276.
3. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R, et al. (2004) Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 39: 233–239.
4. Connolly SA, Jackson JO, Jardetzky TS, Longnecker R, (2011) Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat Rev Microbiol 9: 369–381.
5. Feire AL, Koss H, Compton T, (2004) Cellular integrins function as entry receptors for human cytomegalovirus via a highly conserved disintegrin-like domain. Proc Natl Acad Sci U S A 101: 15470–15475.
6. Wang X, Huong SM, Chiu ML, Raab-Traub N, Huang ES, (2003) Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 424: 456–461.
7. Soroceanu L, Akhavan A, Cobbs CS, (2008) Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 455: 391–395.
8. Vanarsdall AL, Wisner TW, Lei H, Kazlauskas A, Johnson DC, (2012) PDGF receptor-alpha does not promote HCMV entry into epithelial and endothelial cells but increased quantities stimulate entry by an abnormal pathway. PLoS Pathog 8: e1002905.
9. Isaacson MK, Feire AL, Compton T, (2007) Epidermal growth factor receptor is not required for human cytomegalovirus entry or signaling. J Virol 81: 6241–6247.
10. Eisenberg RJ, Atanasiu D, Cairns TM, Gallagher JR, Krummenacher C, et al. (2012) Herpes virus fusion and entry: a story with many characters. Viruses 4: 800–832.
11. Ryckman BJ, Rainish BL, Chase MC, Borton JA, Nelson JA, et al. (2008) Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 82: 60–70.
12. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, et al. (2004) Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78: 10023–10033.
13. Compton T, Nepomuceno RR, Nowlin DM, (1992) Human cytomegalovirus penetrates host cells by pH-independent fusion at the cell surface. Virology 191: 387–395.
14. Sinzger C, (2008) Entry route of HCMV into endothelial cells. J Clin Virol 41: 174–179.
15. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC, (2006) Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol 80: 710–722.
16. Haspot F, Lavault A, Sinzger C, Laib Sampaio K, Stierhof YD, et al. (2012) Human cytomegalovirus entry into dendritic cells occurs via a macropinocytosis-like pathway in a pH-independent and cholesterol-dependent manner. PLoS One 7: e34795.
17. Backovic M, Longnecker R, Jardetzky TS, (2009) Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B. Proc Natl Acad Sci U S A 106: 2880–2885.
18. Heldwein EE, Lou H, Bender FC, Cohen GH, Eisenberg RJ, et al. (2006) Crystal structure of glycoprotein B from herpes simplex virus 1. Science 313: 217–220.
19. Roche S, Rey FA, Gaudin Y, Bressanelli S, (2007) Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science 315: 843–848.
20. Roche S, Bressanelli S, Rey FA, Gaudin Y, (2006) Crystal structure of the low-pH form of the vesicular stomatitis virus glycoprotein G. Science 313: 187–191.
21. Kadlec J, Loureiro S, Abrescia NG, Stuart DI, Jones IM, (2008) The postfusion structure of baculovirus gp64 supports a unified view of viral fusion machines. Nat Struct Mol Biol 15: 1024–1030.
22. Marshall GS, Rabalais GP, Stout GG, Waldeyer SL, (1992) Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis 165: 381–384.
23. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB, (1990) Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64: 1079–1085.
24. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, et al. (2009) Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360: 1191–1199.
25. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, et al. (2011) Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377: 1256–1263.
26. Potzsch S, Spindler N, Wiegers AK, Fisch T, Rucker P, et al. (2011) B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog 7: e1002172.
27. Backovic M, Jardetzky TS, (2009) Class III viral membrane fusion proteins. Curr Opin Struct Biol 19: 189–196.
28. Atanasiu D, Whitbeck JC, de Leon MP, Lou H, Hannah BP, et al. (2010) Bimolecular complementation defines functional regions of Herpes simplex virus gB that are involved with gH/gL as a necessary step leading to cell fusion. J Virol 84: 3825–3834.
29. Wu CH, Apweiler R, Bairoch A, Natale DA, Barker WC, et al. (2006) The Universal Protein Resource (UniProt): an expanding universe of protein information. Nucleic Acids Res 34: D187–191.
30. Scheffzek K, Welti S, (2012) Pleckstrin homology (PH) like domains - versatile modules in protein-protein interaction platforms. FEBS Lett 586: 2662–2673.
31. Stampfer SD, Lou H, Cohen GH, Eisenberg RJ, Heldwein EE, (2010) Structural basis of local, pH-dependent conformational changes in glycoprotein B from herpes simplex virus type 1. J Virol 84: 12924–12933.
32. Spindler N, Rucker P, Potzsch S, Diestel U, Sticht H, et al. (2013) Characterization of a discontinuous neutralizing epitope on glycoprotein B of human cytomegalovirus. J Virol 87: 8927–8939.
33. Meyer H, Masuho Y, Mach M, (1990) The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. J Gen Virol 71 (Pt 10) 2443–2450.
34. Spaete RR, Saxena A, Scott PI, Song GJ, Probert WS, et al. (1990) Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. J Virol 64: 2922–2931.
35. Holm L, Park J, (2000) DaliLite workbench for protein structure comparison. Bioinformatics 16: 566–567.
36. Stanfield RL, Zemla A, Wilson IA, Rupp B, (2006) Antibody elbow angles are influenced by their light chain class. J Mol Biol 357: 1566–1574.
37. Wilson IA, Stanfield RL, (1994) Antibody-antigen interactions: new structures and new conformational changes. Curr Opin Struct Biol 4: 857–867.
38. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, et al. (2012) Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489: 526–532.
39. Wells JA, (1996) Binding in the growth hormone receptor complex. Proc Natl Acad Sci U S A 93: 1–6.
40. Zemlin M, Klinger M, Link J, Zemlin C, Bauer K, et al. (2003) Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J Mol Biol 334: 733–749.
41. Kuroda D, Shirai H, Kobori M, Nakamura H, (2008) Structural classification of CDR-H3 revisited: a lesson in antibody modeling. Proteins 73: 608–620.
42. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, et al. (2012) Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A 109: E3268–3277.
43. Julien JP, Sok D, Khayat R, Lee JH, Doores KJ, et al. (2013) Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 9: e1003342.
44. Cairns TM, Fontana J, Huang ZY, Whitbeck JC, Atanasiu D, et al. (2013) Mechanism of neutralization of HSV by antibodies directed at the fusion domain of glycoprotein B. J Virol 88: 2677–89 doi: 10.1128/JVI.03200-13
45. Sharma S, Wisner TW, Johnson DC, Heldwein EE, (2013) HCMV gB shares structural and functional properties with gB proteins from other herpesviruses. Virology 435: 239–249.
46. Vitu E, Sharma S, Stampfer SD, Heldwein EE, (2013) Extensive mutagenesis of the HSV-1 gB ectodomain reveals remarkable stability of its postfusion form. J Mol Biol 425: 2056–2071.
47. Plate AE, Reimer JJ, Jardetzky TS, Longnecker R, (2011) Mapping regions of Epstein-Barr virus (EBV) glycoprotein B (gB) important for fusion function with gH/gL. Virology 413: 26–38.
48. Cui X, Meza BP, Adler SP, McVoy MA, (2008) Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26: 5760–5766.
49. Axelsson F, Adler SP, Lamarre A, Ohlin M, (2007) Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines. Vaccine 26: 41–46.
50. Kabsch W, (2010) Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr D Biol Crystallogr 66: 133–144.
51. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658–674.
52. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67: 235–242.
53. Schwarzenbacher R, Godzik A, Grzechnik SK, Jaroszewski L, (2004) The importance of alignment accuracy for molecular replacement. Acta Crystallogr D Biol Crystallogr 60: 1229–1236.
54. Krivov GG, Shapovalov MV, Dunbrack RL, Jr (2009) Improved prediction of protein side-chain conformations with SCWRL4. Proteins 77: 778–795.
55. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, et al. (2011) REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 67: 355–367.
56. Zemla A, Zhou CE, Slezak T, Kuczmarski T, Rama D, et al. (2005) AS2TS system for protein structure modeling and analysis. Nucleic Acids Res 33: W111–115.
57. Blom N, Sicheritz-Ponten T, Gupta R, Gammeltoft S, Brunak S, (2004) Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 4: 1633–1649.
58. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, et al. (2008) Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 329: 112–124.
59. Olsson MHM, Sondergaard CR, Rostkowski M, Jensen JH, (2011) PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pK(a) Predictions. Journal of Chemical Theory and Computation. Journal of Chemical Theory and Computation 7: 525–537.
60. Guex N, Peitsch MC, (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714–2723.
61. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65: 712–725.
62. Case DA, Darden TA, Cheatham TE, 3rd, Simmerling C, Wang J, et al. (2010) AMBER11. San Francisco: University of California.
63. Meiselbach H, Horn AHC, Harrer T, Sticht H, (2007) Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations. J Mol Model 13: 297–304.
64. Wartha F, Horn AHC, Meiselbach H, Sticht H, (2005) Molecular dynamics simulations of HIV-1 protease suggest different mechanisms contributing to drug resistance. Journal of Chemical Theory and Computation 1: 315–324.
65. Miyamoto S, Kollman PA, (1992) Settle - an Analytical Version of the Shake and Rattle Algorithm for Rigid Water Models. Journal of Computational Chemistry 13: 952–962.
66. Humphrey W, Dalke A, Schulten K, (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33–38, 33-38, 27-38.
67. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
68. Kleywegt GJ, Jones TA, (1994) Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallogr D Biol Crystallogr 50: 178–185.
69. Bohne-Lang A, von der Lieth CW, (2005) GlyProt: in silico glycosylation of proteins. Nucleic Acids Res 33: W214–219.